Oncotelic, a subsidiary of Mateon Therapeutics, appointed John Sampson, MD, PhD, to its medical advisory board.
Dr. Sampson is a neurosurgeon-scientist who generates drugs for patients with brain tumors and focuses on the development, translation and understanding of immunotherapies.
He will offer advice and guidance to assist the clinical development of the lead anti-brain tumor drug candidate of Oncotelic.
Dr. Sampson is the Robert H. and Gloria Wilkins distinguished chair of the department of neurosurgery at Duke University School of Medicine in Durham, N.C., and the co-leader of the Duke Cancer Institute's neuro-oncology program.
"I very much look forward to working with Dr. Sampson to diligently advance our clinical trial program for brain tumors with the vision of bringing a new and effective treatment option to adult and pediatric patients with recurrent or refractory high grade gliomas," said Fatih Uckun, MD, PhD, CMO of Oncotelic and Mateon.